Using stimulant medication for children with ADHD: what do parents say? A brief report
Alice Charach1, Anna Skyba, Lisa Cook
1Department of Psychiatry, Hospital for Sick Children, Toronto, Ontario, Canada. alice.charach@sickkids.ca
Introduction:
Long-term adherence to stimulant treatment for Attention Deficit Hyperactivity Disorder (ADHD) is frequently poor. Since parents are the key decision makers regarding their child's health care, their thoughts regarding medication use are crucial to whether children take prescribed stimulants. To develop an understanding of what parents think about using stimulants to treat their children's ADHD symptoms we consulted groups of parents about their experiences.
Methods:
Using qualitative methods informed by phenomenology, three focus groups of parents were asked to describe their experiences parenting a child with ADHD and using stimulant medications for treatment. Participants were 17 mothers and fathers of 14 children with ADHD, ages 7-14 years, who had received detailed diagnostic assessments and had used stimulants. Focus group dialogue was recorded and transcribed. Using established methods of data analysis, themes were identified and explored.
Results:
Accepting that one's child has ADHD and needs treatment is a difficult and lengthy process, often accompanied by confusion and self-doubt. Parents find the choice to use stimulant treatment particularly challenging given the conflicting opinions they hear from family, friends and professionals.
Conclusions:
Universally, parents want to do what is best for their child. Adverse effects, concerns about stigmatization, and the child's dislike of taking pills, all contribute to parents' decisions to discontinue medication even when the child shows symptomatic benefit.
More Related Videos
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:29Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
01:25Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:28Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...